|
Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma Clinical research trials and Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma. Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma clinical trial. Participants frequently get the best healthcare available for their Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma  Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma
Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma
For Condition: Asthma,Hypersensitivity
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: Asthma is a chronic inflammatory disorder of the airways characterized by reversible airflow obstruction. Fourteen million persons (6.4%) in the United States report having asthma, and from 1980 to 1994 the prevalence of self-reported asthma in the United States increased by 75%. A major factor in the pathogenesis of asthma is the development of an allergic inflammatory response to inhaled antigens. Interleukin-4 (IL-4) plays a key role in this response by promoting IgE production, upregulating IgE receptors, upregulating adhesion receptors such as VCAM-1, promoting Th2 cell development and increasing mucus secretion. Soluble recombinantly produced IL-4R (sIL-4R) has been shown to bind and inactivate IL-4, both in vitro and in animal models. As part of a multicenter trial, 20 subjects at the NIH site will receive 0.9 mg., 1.8 mg. sIL-4R or placebo once weekly for 12 weeks in a double blind placebo controlled study. Study drug will be delivered via the AERx aerosol drug delivery device. The primary objective of the study will be to evaluate efficacy as measured by FEV1. Secondary objectives will include changes in FVC, FEF 27-75, peak flow, bronchodilator usage, asthma symptoms, quality of life scores, immunologic and inflammatory markers, pharmacokinetics, safety and immunogenicity. The study population will consist of moderate to severe asthmatics on (Beta)-agonist monotherapy with an FEV1 of 50-80% of predicted. After 12 weeks of study drug, subjects will be followed for an additional 8 weeks.
Details: Asthma is a chronic inflammatory disorder of the airways characterized by reversible airflow obstruction. Fourteen million persons (6.4%) in the United States report having asthma, and from 1980 to 1994 the prevalence of self-reported asthma in the United States increased by 75%. A major factor in the pathogenesis of asthma is the development of an allergic inflammatory response to inhaled antigens. Interleukin-4 (IL-4) plays a key role in this response by promoting IgE production, upregulating IgE receptors, upregulating adhesion receptors such as VCAM-1, promoting Th2 cell development and increasing mucus secretion. Soluble recombinantly produced IL-4R (sIL-4R) has been shown to bind and inactivate IL-4, both in vitro and in animal models. As part of a multicenter trial, 20 subjects at the NIH site will receive 0.9 mg., 1.8 mg. sIL-4R or placebo once weekly for 12 weeks in a double blind placebo controlled study. Study drug will be delivered via the AERx aerosol drug delivery device. The primary objective of the study will be to evaluate efficacy as measured by FEV1. Secondary objectives will include changes in FVC, FEF 27-75, peak flow, bronchodilator usage, asthma symptoms, quality of life scores, immunologic and inflammatory markers, pharmacokinetics, safety and immunogenicity. The study population will consist of moderate to severe asthmatics on (Beta)-agonist monotherapy with an FEV1 of 50-80% of predicted. After 12 weeks of study drug, subjects will be followed for an additional 8 weeks.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Male or nonpregnant, non-breastfeeding females age 12-85 years. Diagnosis of persistent asthma for greater than 1 year and currently being treated with short acting beta-2 agonist only. FEV1 50-80% of predicted (must be demonstrated at Day 10 and Day 0). Patients will be stratified into 50-70% or 71-80% cohort at Day 10. Increase of greater than or equal to 15% over baseline FEV1 approximately 15-20 minutes after beta-2 agonist inhalation (2-4 puffs of albuterol via MDI or the nebulized equivalent) documented at baseline. Positive prick skin test to at least two allergens (defined as wheal 3 mm greater than control and erythema greater than control). History of asthma symptoms (wheezing, shortness of breath, cough, chest tightness, or nighttime awakening) on least 3 of the last 7 days. Fulfillment of washout criteria by not using any of the medications listed below for the specified times prior to Day 0 of the study drug treatment: Parenteral corticosteroids for 4 weeks; Oral corticosteroids for 4 weeks; Inhaled corticosteroids for 4 weeks; Cromolyn sodium (Intal), nedocromil (Tilade) for 4 weeks; Theophylline, zileuton (Zyflo), zafirlukast (Accolate), or montelukast (Singulair) for 4 weeks; Astemizole (Hismanal) for 12 weeks; Terfenadine (Seldane), or fexofenadine (Allegra) for 6 days; Cetirizine (Zyrtec) for 6 days; Hydroxyzine (Atarax, Vistaril) for 6 days; Azelastine (Astelin) nasal spray for 6 days; and Salmeterol (Serevent) for 9 days. No clinically significant abnormality in chemistry, hematology, urinalysis: serum creatinine less than or equal to 1.7 mg/dL; total bilirubin less than or equal to 1.5 mg/dL; AST (SGOT), ALT (SGPT) less than or equal to 2 times laboratory's upper limit of normal. No clinically significant abnormality in EKG within 1 month prior to enrollment. No clinically significant abnormality in CXR (other than changes consistent with asthma) within 1 year prior to enrollment. Nonsmoker, for at least 2 years with a smoking history of no more than 10 pack years (e.g., one pack per day for 10 years). Agreement to use medically accepted contraception throughout the study, if sexually active, except females who are postmenopausal for greater than or equal to 2 years. Agreement not to donate blood or blood products throughout the study. Demonstrated ability to follow proper technique in the use of the AERx system. A written, signed, and witnessed consent form. No desensitization therapy within 3 months prior to Day 0 of study drug treatment. No use of any investigational or nonapproved drug therapy within 30 days prior to Day 0 of study drug treatment. No occurrence of acute asthma exacerbation requiring emergency room treatment within 6 weeks of Day 0 of study drug treatment. No occurrence of acute asthma exacerbation requiring hospitalization within 12 months of Day 0 of study drug treatment. No occurrence of respiratory infection which affects asthma within 4 weeks prior to Day 0 of study drug treatment. No history of endotracheal intubation for asthma-related exacerbation within 15 years prior to Day 0 of study drug treatment. No presence of significant medical conditions (including obesity affecting respiratory function, congestive heart failure, myocardial infarction, unstable angina, uncontrolled hypertension, severe pulmonary disease, history of cancer [other than resected cutaneous basal or squamous cell carcinoma], insulin-dependent diabetes, autoimmune disease, or known HIV infection). No previous enrollment in a study of soluble IL-4 receptor. No history of alcohol abuse, drug abuse, or psychiatric illness that would interfere with ability to comply with protocol requirements or give informed consent. No patients experiencing hypersensitivity to soluble IL-4R.
Total Enrollment: 40
Location and Contact Information:
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 990115; 99-I-0115
Study Start Date: May 25, 1999
Record last reviewed: May 14, 1999
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001909
Other Asthma Studies:
1. Segmental Bronchoalveolar Lavage
2. Borage Oil and Ginkgo Biloba (EGb 761) in Asthma
3. Long-term Safety Performance of Fexofenadine in Asthma
4. Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older with Asthma
5. Intervention to Improve Asthma Management/Prevention
Related Studies:
Other Asthma Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Phase II Efficacy Study of Aerosolized Recombinant Human IL-4 Receptor in Asthma
|
|
|
|
|
|
|
|
